How much does one injection of Polatuzumab cost?

Polatuzumab is a new antibody-drug conjugate (ADC) mainly used to treat patients with refractory or relapsed diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). By targeting the CD79b receptor on the surface of B cells, it accurately delivers cytotoxic drugs into tumor cells to selectively kill tumors while minimizing damage to normal cells. This innovative drug mechanism makes it another important treatment method after traditional chemotherapy. Since its approval by the U.S. FDA in June 2019, vepotuzumab has been approved in many countries around the world and has gradually entered the Chinese market.

In the domestic market, vepotuzumab has been included in the medical insurance reimbursement catalog, providing patients with certain economic protection. The current specifications on the domestic market are 30mg per injection, and the market reference price is about 10,000 yuan, but the specific reimbursement amount will vary according to regional medical insurance policies. Patients should refer to the hospital pharmacy prices and medical insurance policies when actually purchasing medicines. Compared with overseas markets, the price of the same specifications in the U.S. market is approximately US$3,900, which is equivalent to about 28,000 yuan. The price difference is mainly affected by exchange rates, market policies and medical insurance coverage. Currently, there is no generic version of Vepotolizumab on the market. Therefore, if patients need medication, they can only purchase the original drug through regular channels, which also ensures the quality and efficacy of the drug.

From the perspective of price rationality, the pricing of vepotuzumab is closely related to its complex pharmaceutical process and high research and development costs. As an ADC drug, it not only requires highly purified monoclonal antibodies, but also requires stable chemical coupling technology so that cytotoxic drugs can be accurately delivered to tumor cells. High overseas prices reflect technical barriers and patent protection, while domestic medical insurance coverage significantly reduces the actual burden on patients, which is part of my country's push to make innovative drugs more accessible in recent years.

Reference materials:https://www.drugs.com/polivy.html